【Case Study】Why do disease model mice change the outcomes?

If you are considering using a lung fibrosis model in a drug efficacy study, you can maximize the efficacy of your compound by using a disease induction model that is appropriate for your evaluation, rather than using a standard pathological model.


Today, we will provide a clear overview of the disease induction periods in IPF studies and the diversity of the mice’s ages.


We pride ourselves on our high-level technical use of micro sprayers in our models, and we are often asked to conduct studies by researchers after they are dissatisfied with the work done by other companies. We have conducted more than 150 studies to date and have had our results posted in many publications.


The following table shows the mice’s ages and the various disease induction periods used in IPF studies.



  • Young x Standard type: If you would like to see the effect on pulmonary fibrosis first
  • Aged x Standard type: When you would like to use mice with low fibrosis repair capabilities.
  • Young x Chronic type: When long-term administration is required, e.g. for cell therapy.



Below you will also find the results of the young x Standard type that which have been previously conducted and published by MediciNova, Inc.

MediciNova, Inc, ICLAF poster, 2014


The compound is currently in a Phase II clinical trial and is being used to evaluate fibrosis using lung hydroxyproline and CT analysis.


We can give you a rough cost estimate for any study if you provide us with a description of your model type and your study preferences.


If you are interested and would like to know the approximate costs of these plans, please contact us.